SOURCE: Xact Aid Inc.

November 01, 2005 15:06 ET

Xact Aid, Inc. Acquires STD Test

WESTLAKE VILLAGE, CA -- (MARKET WIRE) -- November 1, 2005 -- Xact Aid, Inc. (OTC BB: XAID) is pleased to announce the acquisition of the Patent Pending STD (Sexually Transmitted Disease) Test "STD Alert." STD Alert is a urine-based test inside a self-contained cup that is specially designed and outfitted to be used to rapidly test for sexually transmitted diseases.

The Company is presently initiating tests, with the goal of having STD Alert able to detect Chlamydia, which, according to the Center for Disease Control (C.D.C.) is one of the most widespread STD in the U.S. If approved by the FDA, STD Alert would be the first urine based self-contained cup rapid test in the world for Chlamydia.

Xact Aide CEO Robert Pautsch says, "It is our goal to help in the fight against Sexually Transmitted Diseases and STD Alert might be a major step in mitigating the long-term effects of Chlamydia through early detection.

About Xact Aid, Inc

Xact Aid Inc is a biomedical firm focusing on life science solutions for the sexually transmitted disease marketplace.

For more information please visit our website at www.xactaid.com or contact Ben Kirk at (800) 605-1577.

Safe Harbor

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

Contact Information

  • Contact:
    Ben Kirk
    (800) 605-1577